Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alexion Pharmaceuticals has purchased patents and assets of the investigational cPMP replacement therapy from the Germany-based development-stage biotechnology company Orphatec Pharmaceuticals for an upfront cash payment of around $3m in addition to contingent payments.
Subscribe to our email newsletter
The cPMP replacement therapy is designed to treat patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare genetic disorder characterized severe brain damage and rapid death in newborns.
Alexion has also formed a research collaboration with key MoCD researchers from Orphatec to accelerate the development of this therapy.
Alexion CEO Leonard Bell said the company was dedicated to expeditiously investigate the potential of such an innovative therapy.
Orphatec MoCD original team leader, professor and chair in Biochemistry of the Germany-based Department of Chemistry & Center for Molecular Medicine Guenter Schwarz said Alexion’s proven expertise in developing drugs for ultra-rare disorders brings hope for the work begun by the Orphatec team.